SG11201703152RA - Reducing viscosity of pharmaceutical formulations - Google Patents

Reducing viscosity of pharmaceutical formulations

Info

Publication number
SG11201703152RA
SG11201703152RA SG11201703152RA SG11201703152RA SG11201703152RA SG 11201703152R A SG11201703152R A SG 11201703152RA SG 11201703152R A SG11201703152R A SG 11201703152RA SG 11201703152R A SG11201703152R A SG 11201703152RA SG 11201703152R A SG11201703152R A SG 11201703152RA
Authority
SG
Singapore
Prior art keywords
pharmaceutical formulations
reducing viscosity
viscosity
reducing
formulations
Prior art date
Application number
SG11201703152RA
Other languages
English (en)
Inventor
Christopher James Sloey
Sekhar Kanapuram
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201703152R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11201703152RA publication Critical patent/SG11201703152RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201703152RA 2014-10-23 2015-10-22 Reducing viscosity of pharmaceutical formulations SG11201703152RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462067637P 2014-10-23 2014-10-23
PCT/US2015/056972 WO2016065181A1 (en) 2014-10-23 2015-10-22 Reducing viscosity of pharmaceutical formulations

Publications (1)

Publication Number Publication Date
SG11201703152RA true SG11201703152RA (en) 2017-05-30

Family

ID=54427875

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201703152RA SG11201703152RA (en) 2014-10-23 2015-10-22 Reducing viscosity of pharmaceutical formulations

Country Status (17)

Country Link
US (2) US11813328B2 (ko)
EP (2) EP3209332B1 (ko)
JP (3) JP2017531682A (ko)
KR (1) KR102534017B1 (ko)
CN (2) CN107206070B (ko)
AU (2) AU2015335743B2 (ko)
BR (1) BR112017008125B1 (ko)
CA (1) CA2964786C (ko)
CL (2) CL2017000984A1 (ko)
EA (3) EA033444B1 (ko)
ES (1) ES2964713T3 (ko)
IL (2) IL287947B1 (ko)
MA (1) MA54716A (ko)
MX (2) MX2017005243A (ko)
SG (1) SG11201703152RA (ko)
WO (1) WO2016065181A1 (ko)
ZA (1) ZA201702762B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2964713T3 (es) 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
US11459401B2 (en) 2016-10-06 2022-10-04 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
JP7377596B2 (ja) * 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
WO2018201064A1 (en) 2017-04-28 2018-11-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
US20200352857A1 (en) 2017-04-28 2020-11-12 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CA3075977A1 (en) * 2017-09-22 2019-03-28 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
WO2019106206A1 (en) 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
MX2021000037A (es) 2018-07-05 2021-03-25 Bayer Ag Nueva formulacion estable de alta concentracion para anticuerpos anti-fxia.
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
AU2020263318A1 (en) * 2019-04-23 2021-10-21 Amgen Inc. The use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
JP2001522814A (ja) * 1997-11-07 2001-11-20 カイロン コーポレイション 増大されたｉｇｆ−ｉ溶解性を提供する組成物
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6159485A (en) * 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
MXPA02009485A (es) 2000-03-31 2003-03-10 Kirin Brewery Preparacion en polvo para administracion a traves de la mucosa, que comprende un farmaco de alto peso molecular y que muestra una estabilidad mejorada en almacenamiento.
CZ20031259A3 (cs) 2000-11-07 2004-01-14 Chiron Corporation Stabilizované interferonové prostředky
PL217752B1 (pl) 2001-08-23 2014-08-29 Genmab As Izolowane ludzkie przeciwciało monoklonalne wobec IL-15 lub jego fragment wiążący antygen i związane z nimi hybrydoma, kompozycja farmaceutyczna oraz zastosowania medyczne
ES2311094T3 (es) 2002-02-27 2009-02-01 Immunex Corporation Composicion estabilizada de tnfr-fc que comprende arginina.
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
AU2004207003A1 (en) 2003-01-30 2004-08-12 Medimmune, Llc Anti-integrin alphanubeta3 antibody formulations and uses thereof
CN102258464A (zh) * 2003-04-04 2011-11-30 健泰科生物技术公司 高浓度抗体和蛋白制剂
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
WO2007134181A2 (en) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US8232372B2 (en) 2006-12-14 2012-07-31 Schering Corp. Engineered anti-TSLP antibody
EA201000006A1 (ru) 2007-06-20 2010-10-29 Айрм Ллк Способы и композиции для лечения аллергических заболеваний
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
WO2009073569A2 (en) * 2007-11-30 2009-06-11 Abbott Laboratories Protein formulations and methods of making same
KR20100120289A (ko) * 2008-01-15 2010-11-15 애보트 게엠베하 운트 콤파니 카게 분말상 단백질 조성물 및 이의 제조 방법
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP2011067202A (ja) 2009-08-31 2011-04-07 Sanyo Chem Ind Ltd タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及びタンパク質の安定化方法
BR112012011539A8 (pt) * 2009-11-17 2017-12-26 Ipsen Pharma Sas formulação para a combinação de hgh e rhigf-1
WO2011095543A1 (en) 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
AU2011219715B2 (en) * 2010-02-26 2014-12-11 Novo Nordisk A/S Stable antibody containing compositions
WO2011109415A2 (en) 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
BR112012027828A2 (pt) * 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US9574005B2 (en) 2011-07-19 2017-02-21 Chugai Seiyaku Kabushiki Kaisha Stable Protein-containing preparation containing argininamide or analogous compound thereof
CN104023748B (zh) * 2011-10-28 2018-03-02 诚信生物公司 含有氨基酸的蛋白质制剂
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US20150150982A1 (en) 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
US20150004174A1 (en) 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
ES2964713T3 (es) 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
EP3763384A1 (en) 2014-12-03 2021-01-13 CSL Behring AG Pharmaceutical product with increased stability comprising immunoglobulins
EP3519439A2 (en) 2016-09-29 2019-08-07 Amgen Inc. Low-viscosity antigen binding proteins and methods of making them
US11459401B2 (en) 2016-10-06 2022-10-04 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法

Also Published As

Publication number Publication date
ZA201702762B (en) 2022-12-21
AU2021200990A1 (en) 2021-03-11
IL251726A0 (en) 2017-06-29
EP3909611A1 (en) 2021-11-17
JP2020037559A (ja) 2020-03-12
JP6965321B2 (ja) 2021-11-10
US20170333559A1 (en) 2017-11-23
US20240066124A1 (en) 2024-02-29
CN114569716A (zh) 2022-06-03
EP3909611B1 (en) 2023-08-30
BR112017008125B1 (pt) 2023-11-21
EA202191513A1 (ru) 2021-11-30
IL287947A (en) 2022-01-01
CN107206070B (zh) 2022-01-18
MA54716A (fr) 2021-11-17
WO2016065181A1 (en) 2016-04-28
CA2964786C (en) 2023-10-17
AU2015335743A1 (en) 2017-05-04
JP2022009223A (ja) 2022-01-14
EA033444B1 (ru) 2019-10-31
EA038462B1 (ru) 2021-08-31
US11813328B2 (en) 2023-11-14
EP3209332B1 (en) 2021-05-26
ES2964713T3 (es) 2024-04-09
AU2015335743B2 (en) 2020-12-24
CL2017000984A1 (es) 2018-01-05
AU2021200990B2 (en) 2023-02-16
EA201991447A1 (ru) 2019-11-29
CL2019002190A1 (es) 2019-11-22
KR102534017B1 (ko) 2023-05-19
KR20170071518A (ko) 2017-06-23
JP7411615B2 (ja) 2024-01-11
IL251726B (en) 2021-12-01
EP3209332A1 (en) 2017-08-30
CN107206070A (zh) 2017-09-26
CA2964786A1 (en) 2016-04-28
JP2017531682A (ja) 2017-10-26
IL287947B1 (en) 2024-04-01
BR112017008125A2 (pt) 2018-06-19
MX2017005243A (es) 2017-08-18
MX2021015789A (es) 2022-01-27
EA201790787A1 (ru) 2017-08-31

Similar Documents

Publication Publication Date Title
IL287947A (en) Viscosity reduction of pharmaceutical preparations
IL246978A0 (en) New paracetamol formulations
HK1225655A1 (zh) 包含azd9291的藥用組合物
GB201618482D0 (en) Pharmaceutical compositions
GB201419257D0 (en) Pharmaceutical compositions
GB201409471D0 (en) Pharmaceutical composition
IL249553A0 (en) Pharmaceutical preparations
ZA201606075B (en) Pharmaceutical compositions of sitagliptin
HK1252534A1 (zh) 來氟米林的可注射藥物組合物
GB201718468D0 (en) Stable liquid pharmaceutical compositions of bortezomb
PL3122330T3 (pl) Kompozycje farmaceutyczne zawierające lewocetyryzynę
IL250817A0 (en) pharmaceutical preparations
IL267279A (en) Pharmaceutical formulations of suvorexant
GB201506755D0 (en) Novel pharmaceutical formulation
PL3200772T3 (pl) Kompozycje farmaceutyczne zawierające alpelisyb
GB201417589D0 (en) Pharmaceutical Formulations
GB201400117D0 (en) Pharmaceutical composition
GB201407741D0 (en) Novel drug formulation
SG2014014872A (en) Pharmaceutical compositions
GB201400951D0 (en) Novel drug formulation
GB201408432D0 (en) Pharmaceutical compositions